India ranked by international pharma as the third most competitive nation19 Nov 2017
Perception of India’s API manufacturing seems to be improving.
CPhI & P-MEC India – organised by UBM – is set to welcome more than 50,000 attendees as the CPhI Global Pharma Index shows the country’s efforts to improve its reputation are paying dividends. India emerged successful in a number of key areas and was ranked by international pharma companies as the third most competitive nation globally.
The inaugural CPhI Global Pharma Index – a reputation audit – draws on the insights of 500 international pharmaceutical companies from over 40 countries to rank the major pharma economies out of 10 across a spread of criteria.
These findings are announced in the 11th annual CPhI & P-MEC India 2017 is set to open later this month in Mumbai (27-30 November 2017). It is a key time for the Indian industry, with the second India Pharma Week returning (25-30 November 2017), which will feature seven events covering the entire pharma supply chain in India, leveraging Mumbai’s status as a major pharma hub. Such has been the growth in India over the last year, CPhI & P-MEC India now runs across two exhibition centres simultaneously – the Bombay Exhibition Centre (BEC) and the MMRDA Grounds (BKC) – and has expanded from a three- to a four- day event.
Encouragingly, India was rated second globally for predicted ‘pharma market growth potential’, with respondents citing high growth domestic markets and expanding manufacturing exports as key drivers. India received a score of 7.0, narrowly behind China (7.2). However, India was rated by pharmaceutical companies as having nearly twice the potential of Western European countries, significantly outpacing even the US (6.3), Korea (6), and Germany (5.9), who finished third, fourth, and fifth respectively.
In fact, the confidence in India was such that the country was chosen as the third most competitive pharma business destination, with a score of 6.3, behind only the US (6.9) and Germany (6.6), but ahead of Japan and – chief rival – China.
India’s recent efforts to increase pharmaceutical manufacturing quality also appear to be having an effect. The perception of India’s API manufacturing seems to be improving, with the industry believing India is broadly comparable to Italy, Spain, and Korea, though it is still behind tier one nations such as Germany and the US.
For ‘quality and knowledge’ of pharmaceutical professionals, India (6.2) came notably ahead of China, Korea and Spain, and at a comparable level to that of Italy (6.5). Interestingly, and perhaps highlighting India’s efforts in patented and biosimilar drug development, the country also demonstrated growth in the category of ‘innovativeness’, which remains a key component for the creation of new medicines. In this category, India finished a little behind Korea and France, and ahead of Italy and Spain.
A more detailed analysis of only domestic respondents showed that the vast majority (80%) were either ‘confident’ or ‘extremely confident’ in their business outlook for India’s market in 2018. Notably, the CPhI report also found that 88% of respondents in India ‘were looking to work with foreign partners in 2018’, with on average 50% of sales to foreign companies. Highlighting this increased internationalization, exhibitor numbers have grown by more than 200 companies in the last year, with the 2017 event featuring 1400 exhibitors from over 100 countries.
“Ultimately, the fundamentals of progression in the country are extremely strong – boasting over 24,000 pharmaceutical companies, and 10,500 plants – coupled with Government support, increased investment and an improving regulatory reputation, there is a real sense amongst attendees at CPhI & P-MEC India that the country’s pharma sector is preparing to enter the next stage in its advancement. This event is the perfect place for companies to explore the latest trends and innovations the market has to offer and meet the movers and shakers in the domestic and international pharma machinery, technology and ingredients industries,” commented Rutger Oudejans, Brand Director Pharma at UBM.
Innovation awarded at Pharmapack
10 Feb 2020
Innovations across primary and secondary packaging, drug delivery devices, and machinery acknowledged in Exhibitor Innovations, with Health Product Awards for patient-centricity and eco-design.Read more
Digital value-added medicines - a key driver for 2020
29 Jan 2020
Pharmapack also identifies waste management and the use of blockchain as key trends for the year ahead.Read more
CPhI and AAPS partner to expand expert scientific content at CPhI North America
10 Jan 2020
CPhI and the American Association of Pharmaceutical Scientists (AAPS) today announced a partnership to expand the scientific content of activities sponsored by CPhI, including CPhI North America—the only event to bring the entire North American pharmac...Read more
Innovation and regulatory harmonisation to drive Indian pharma in 2020
18 Dec 2019
Experts suggest the continued goal of aligning India to Western regulatory standards will help the country sustain significant increases in exports.Read more
Connectivity, customization and sustainability driving packaging and drug delivery in 2020
4 Dec 2019
Pharmapack 2020 gathering top specialists and pioneers to exchange their vision on best strategies to tackle key challenges.Read more
Worldwide event predicts global pharma trends for 2020
27 Nov 2019
Content sessions identify value-added medicines, preventive drugs, early diagnostics and patient experience as some of the trends for the year ahead.Read more
India pharma forecast to grow strongly in 2020
22 Nov 2019
The rise in exports growth potential is believed to be in response to concerted reforms by the CDSCO and industry quality improvements in the last few years.Read more
Winners of the 16th Pharma Awards
11 Nov 2019
Companies and individuals from across the whole pharma supply chain recognised for their excellence and commitment.Read more
CDMOs to benefit from rising BTDs, orphan drugs and fast track status therapies
8 Nov 2019
But personalized medicines will require new logistics and manufacturing systems.Read more
Europe predicted to surpass the US in biologic manufacturing capacity by 2023
6 Nov 2019
Demand for biological manufacturing is growing faster than capacity growth.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation